Sonobe Masato, Hattori Koji, Tomita Naohide, Yoshikawa Takafumi, Aoki Hideyuki, Takakura Yoshinori, Suguro Toru
Department of Orthopaedic Surgery, Toho University School of Medicine 6-11-1 Omorinishi, Ota-ku, Tokyo 143-8541, Japan.
Biomed Mater Eng. 2005;15(4):261-7.
Recent studies have reported that statins, inhibitors of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, increase bone formation in osteoblasts in vitro, suggesting that statins may have a new therapeutic application in the treatment of osteoporosis. During the reparative phase of healing of bone fractures, bone marrow-derived mesenchymal stem cells differentiate into osteoblasts or chondrocytes to form callus. If statins also stimulate bone formation in bone marrow-derived mesenchymal stem cells they may have beneficial effects in the treatment of bone fractures. In this study, we assessed the effect of statins on bone formation in rat bone marrow-derived mesenchymal stem cells in vitro. The statins fluvastatin, simvastatin and pravastatin did not significantly enhance mineralization, alkaline phosphatase (ALP) activity and bone gra protein (BGP, osteocalcin). These findings suggest that statins do not increase bone formation in bone marrow-derived mesenchymal stem cells.
最近的研究报道，羟甲基戊二酰辅酶A（HMG-CoA）还原酶抑制剂他汀类药物可在体外增加成骨细胞的骨形成，这表明他汀类药物可能在骨质疏松症治疗方面有新的治疗应用。在骨折愈合的修复阶段，骨髓来源的间充质干细胞分化为成骨细胞或软骨细胞以形成骨痂。如果他汀类药物也能刺激骨髓来源的间充质干细胞的骨形成，那么它们可能对骨折治疗有有益作用。在本研究中，我们评估了他汀类药物对大鼠骨髓来源的间充质干细胞体外骨形成的影响。氟伐他汀、辛伐他汀和普伐他汀并未显著增强矿化、碱性磷酸酶（ALP）活性和骨钙素（BGP，骨钙素）。这些发现表明，他汀类药物不会增加骨髓来源的间充质干细胞的骨形成。
